Capital Analysts LLC’s Myriad Genetics MYGN Stock Holding History

Capital Analysts LLC’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$5K	–	1022
2023 Q1	$5K	Hold	200	–	–	﹤0.01%	867
2022 Q4	$3K	Hold	200	–	–	﹤0.01%	961
2022 Q3	$4K	Hold	200	–	–	﹤0.01%	921
2022 Q2	$4K	Hold	200	–	–	﹤0.01%	890
2022 Q1	$5K	Hold	200	–	–	﹤0.01%	823
2021 Q4	$6K	Sell	200 -200	-50%	-$5.79K	﹤0.01%	865
2021 Q3	$13K	Hold	400	–	–	﹤0.01%	763
2021 Q2	$12K	Hold	400	–	–	﹤0.01%	724
2021 Q1	$12K	Buy	+400	New	+$11.4K	﹤0.01%	771
2020 Q4	–	Sell	-200	Closed	-$3K	–	785
2020 Q3	$3K	Hold	200	–	–	﹤0.01%	691
2020 Q2	$2K	Hold	200	–	–	﹤0.01%	665
2020 Q1	$3K	Hold	200	–	–	﹤0.01%	619
2019 Q4	$5K	Hold	200	–	–	﹤0.01%	617
2019 Q3	$5K	Hold	200	–	–	﹤0.01%	609
2019 Q2	$6K	Hold	200	–	–	﹤0.01%	576
2019 Q1	$6K	Hold	200	–	–	﹤0.01%	557
2018 Q4	$6K	Hold	200	–	–	﹤0.01%	503
2018 Q3	$9K	Hold	200	–	–	﹤0.01%	448
2018 Q2	$7K	Hold	200	–	–	﹤0.01%	493
2018 Q1	$6K	Hold	200	–	–	﹤0.01%	487
2017 Q4	$7K	Buy	+200	New	+$6.75K	﹤0.01%	406

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Capital Analysts LLC's MYGN Position: Q2 2023 in Review

Capital Analysts LLC sold out of Myriad Genetics (MYGN) in Q2 2023, closing a stake of 200 shares — an estimated $5K sold.

Capital Analysts LLC first reported a position in MYGN in Q4 2017 and held it in 21 quarters. The position peaked at $13K in Q3 2021. 188 funds tracked by Wall St. Rank hold MYGN as of Q2 2023.

Capital Analysts LLC reported no remaining Myriad Genetics position as of Q2 2023 after selling out during the quarter.
Capital Analysts LLC sold 200 Myriad Genetics shares in Q2 2023, an estimated $5K.
Capital Analysts LLC first reported a position in Myriad Genetics in Q4 2017 and held it in 21 quarters.
Capital Analysts LLC's Myriad Genetics position peaked at $13K in Q3 2021.
188 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2023.

Based on Capital Analysts LLC's 13F filing for Q2 2023, filed 11 Aug 2023.